# Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients

> **NCT03079219** · PHASE3 · COMPLETED · sponsor: **CCTU** · enrollment: 120 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Experimental drug: Aprepitant
- **DRUG:** Experimental drug: Ondansetron
- **DRUG:** Experimental drug: Dexamethasone
- **DRUG:** Experimental drug: Olanzapine
- **DRUG:** Standard: Aprepitant
- **DRUG:** Standard: Ondansetron
- **DRUG:** Standard: Dexamethasone

## Key facts

- **NCT ID:** NCT03079219
- **Lead sponsor:** CCTU
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-23
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03079219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03079219, "Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03079219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*